Clinical trial · Observational
Liquid Biopsy in Hepatocellular Carcinoma
Assessment of Response to Locoregional Therapy Using Liquid Biopsy in Patients With Hepatocellular Carcinoma
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Circulating tumor DNA (ctDNA) carrying tumor-specific sequence alterations has been found in the cell-free fraction of blood. Hepatocellular carcinoma (HCC) specimens are difficult to obtain, and noninvasive methods are required to assess cancer progression and characterize underlying genomic features. Use of 'liquid biopsy' by assessing circulating cell free DNA enables the clinician to offer targeted immunotherapy or signaling pathway inhibitors. It also offers a model to prove response to locoregional or immunotherapy therapy and predict tumor recurrence non-invasively.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hepatic Carcinoma Malignant Primary Non-Resectable | Hepatocellular Carcinoma | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Cell Free DNA | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Unresectable HCC undergoing locoregional therapy
- description
- Patients with unresectable HCC who have no curative option like tumour ablation, resection or transplantation and are being taken for locoregional therapy will be recruited
- interventionNames
- Diagnostic Test: Cell Free DNA
Primary outcomes (2)
- measure
- Comparison of exome sequencing of primary tumor tissue and cell-free DNA from plasma samples
- timeFrame
- 0, 90 days
- measure
- Serial Quantification of ctDNA in plasma samples by means of real-time PCR post treatment
- timeFrame
- 90 days
Secondary outcomes (2)
- measure
- Time to first recurrence (local or distant) diagnosed on follow up dynamic imaging.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: * Hepatocellular carcinoma BCLC stages B and C of all aetiology, unresectable * Age 18-70 years of either sex Exclusion Criteria: * Contemplating Hepatic resection or OLT * Refractory ascites * Severe Coagulation disorders prior to the procedure (PTI \<70% and Platelet count \< 80,000/mm3) * Hepato-Renal syndrome * Chronic Kidney Disease * Acute decompensation like Hepatic encephalopathy and variceal bleeding * Any known malignancy other than HCC * Life expectancy \< 6 months
References
Publications (0)
Data not yet available